Brain perfusion in fibromyalgia patients and its differences between responders and poor responders to gabapentin
نویسندگان
چکیده
منابع مشابه
Brain perfusion in fibromyalgia patients and its differences between responders and poor responders to gabapentin
INTRODUCTION The aim of the present study was to determine the brain areas associated with fibromyalgia, and whether pretreatment regional cerebral blood flow (rCBF) can predict response to gabapentin treatment. METHODS A total of 29 women with fibromyalgia and 10 healthy women (without pain) matched for age were finally enrolled in the study. Technetium-99m ethyl cysteinate dimer single phot...
متن کاملDHEA administration in poor responders.
may have been influenced by the presence of M540 bodies. M540 bodies are indeed mysterious structures. They stain positively with merocyanine, a fluorescent membrane probe normally associated with the measurement of membrane potential and disorder, and also generate signals in the TUNEL assay, even though these structures do not stain with DNA sensitive fluorochromes such as YOPRO-1 (Marchiani ...
متن کاملPretreatment cognitive and neural differences between sapropterin dihydrochloride responders and non-responders with phenylketonuria
Sapropterin dihydrochloride (BH4) reduces phenylalanine (Phe) levels and improves white matter integrity in a subset of individuals with phenylketonuria (PKU) known as "responders." Although prior research has identified biochemical and genotypic differences between BH4 responders and non-responders, cognitive and neural differences remain largely unexplored. To this end, we compared intelligen...
متن کاملResponders and non-responders to probiotic interventions
"Responders and non-responders to probiotic interventions" (2010).
متن کاملComparison of HCV Plus-and Minus-Strand RNA in PBMCs of Responders and non-Responders of Chronically Infected Patients Receiving Ribavirin and Interferon Therapy
Background and Aims: Hepatitis C virus (HCV) can cause hepatocellular carcinoma (HCC) in a significant proportion (≈ 20 %) of individuals with chronic HCV infection (CHC). Currently, CHC is treated with peginterferon and ribavirin, which depending on genotype approximately 50 to 70% of patients are cured. The so-called “extrahepatic HCV infection” or viral replication in regio...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Arthritis Research & Therapy
سال: 2012
ISSN: 1478-6354
DOI: 10.1186/ar3673